Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Nehad Soloman (NPI 1356302962)

Field	Value
Entity Type	Individual
Organization	Nehad Soloman
Address	9520 W Palm Ln Ste 220
City	Phoenix
State	AZ
ZIP	85037
Taxonomy	Rheumatology Physician
NPI Enumerated	March 31, 2006

Payer Source	Total Paid
Medicare	$5.1M
Medicaid	$0

Key Findings

This provider’s revenue base is effectively single‑payer: total Medicare revenue is $5.1M and there is no Medicaid billing on file. That concentration makes Medicare utilization and reimbursement policy the primary commercial driver for this practice. The NPI was enumerated 2006-03-31 (~20 years ago), indicating an established presence in the market.

Revenue is highly concentrated in a few infused specialty drugs: the precomputed top 3 Medicare codes (J3262, J0129, J3111) account for 45.2% of this provider’s total Medicare revenue. Individually those codes show large dollar contributions — J3262 $846.8K (16.5%), J0129 $743.8K (14.5%), and J3111 $720.7K (14.1%) — which together drive nearly half of Medicare dollars reported.

The code mix and high shares for biologic J‑codes signal an infusion‑centric rheumatology service line: high‑revenue items include J3262 (tocilizumab), J0129 (abatacept), J3111 (romosozumab), J0897 (denosumab), and J1602 (golimumab). In addition, chemotherapy administration codes such as 96413 (1.3K claims, $98 avg paid/claim, $130.4K revenue (2.5%) — ranks #18 of 7514 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code)) and 96401 (1.4K claims, $54 avg paid/claim, $74.5K revenue (1.5%) — ranks #23 of 3868 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code)) point to an on‑site infusion/administration capability beyond routine office visits.

Several individual codes show statistically extreme volume relative to national peers, indicating this practice is a high‑volume national outlier on select items: J3262 ranks #9 of 618 providers nationally (99th percentile; extreme outlier), J0897 ranks #51 of 10057 providers nationally (100th percentile; extreme outlier), and 99214 ranks #924 of 479517 providers nationally (100th percentile; extreme outlier). These high ranks across both drug and E/M codes suggest volumes far above typical national peers for key service lines.

Not all high‑revenue lines are outliers; some biologic and lab codes appear at more typical levels for peers. For example, J0129 (21.9K claims, $34 avg paid/claim, $743.8K revenue (14.5%)) ranks #111 of 1221 providers nationally (91th percentile; typical, unremarkable volume for this code), J0490 ranks #6 of 39 providers nationally (87th percentile; typical, unremarkable volume), and J0717 ranks #265 of 848 providers nationally (69th percentile; typical, unremarkable volume), indicating a mix of unusually high activity on certain drugs and conventional volumes on others.

Operationally, the claim‑level pattern includes very high unit counts with low per‑unit payments for some products (for example J3262 shows 169.4K claims, $5 avg paid/claim, $846.8K revenue (16.5%)). This combination of high claim counts and low per‑claim dollars is consistent with per‑mg or per‑unit reporting of biologic products and implies an operational workflow focused on frequent dispensing/administration of small‑unit billed agents.

The provider’s service mix creates sensitivity to formulary and reimbursement shifts because nearly half of Medicare dollars are tied to three codes (45.2% concentrated in J3262, J0129, J3111). Any changes in coverage, unit pricing, or utilization patterns for these specific biologics would have an outsized impact on the practice’s Medicare revenue.

Taken together, the long tenure (NPI enumerated 2006-03-31 (~20 years ago)), the infusion‑heavy code mix, and multiple national outlier rankings indicate an established rheumatology practice operating a substantial infusion/administration capability for high‑cost biologics and related procedures. Analysts evaluating competitive standing should treat this provider as a major, high‑volume participant on several biologic infusion codes while recognizing that some ancillary services remain at typical peer levels.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

65 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	169,360	$10	$846.8K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	21,880	$30	$743.8K
J3111	Injection, romosozumab-aqqg, 1 mg	90,090	$10	$720.7K
J0897	Injection, denosumab, 1 mg	37,380	$20	$710.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	62,090	$10	$620.9K
J0490	Injection, belimumab, 10 mg	8,350	$40	$325.6K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	68,200	$1	$272.8K
J9312	Injection, rituximab, 10 mg	3,780	$60	$237.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,190	$90	$199.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,330	$100	$130.4K

Showing 1–10 of 65

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Nehad Soloman — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

65 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	5	30	14,700	$30	$494.5K
J3262	2	20	74,500	$1	$367.2K
J0490	1	10	8,350	$40	$327K
J1602	3	30	24,040	$10	$316.2K
J0717	6	20	36,100	$1	$246.6K
J9312	7	20	3,250	$60	$212.6K
J3111	1	40	19,530	$10	$178.8K
J0897	2	260	2,940	$20	$115.6K
J1745	19	40	2,980	$30	$103.9K
86235	9	20	130	$20	$59.5K

Showing 1–10 of 65

Related Providers

Other providers that share a Tax Identification Number (TIN) with Nehad Soloman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arizona Arthritis & Rheumatology Associates P C	AZ	Rheumatology Physician	$0	$11.2M
Alexander Hu	AZ	Internal Medicine Physician	$3.8M	$0
Areena Swarup	AZ	Rheumatology Physician	$3.6M	$0
Saima Chohan	AZ	Rheumatology Physician	$3.5M	$0
Nikila Kumar	AZ	Rheumatology Physician	$3M	$0
John Tesser	AZ	Rheumatology Physician	$3M	$0
Daniel Kreutz	AZ	Rheumatology Physician	$2.8M	$0
Mona Amin	AZ	Rheumatology Physician	$2.7M	$0
Joonhee Lim	AZ	Rheumatology Physician	$2.3M	$0
Andrew Sharobeem	AZ	Rheumatology Physician	$2.3M	$0

Nearby Providers

Other providers in the same ZIP code as Nehad Soloman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Banner Estrella Medical Center	AZ	General Acute Care Hospital	$0	$108M
Therapy Tree, PLLC	AZ	Hearing and Speech Clinic/Center	$0	$54.6M
Desert Valley Pediatrics	AZ	Pediatrics Physician	$0	$21.2M
Pedro Denga	AZ	Contractor	$0	$20.7M
Arizona Surgical Specialists Center, LLC	AZ	Ambulatory Surgical Clinic/Center	$1.4M	$8.1M
Southwest Kidney Davita Dialysis Partners LLC	AZ	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$7.3M
Healthy Life Corporation	AZ	Family Medicine Physician	$0	$6.8M
Clear Vision Ophthalmology PC	AZ	Ophthalmology Physician	$0	$6.3M
Az Pediatric Care	AZ	Primary Care Clinic/Center	$0	$6.3M
Southwest Network, Inc.	AZ	Community/Behavioral Health Agency	$0	$6.1M

Nehad Soloman — Billing Profile & Reimbursement Data

Sign up for Nehad Soloman — Billing Profile & Reimbursement Data policy alerts

Nehad Soloman — Billing Profile & Reimbursement Data

Sign up for Nehad Soloman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References